SEARCH

SEARCH BY CITATION

Reference

  • 1
    Morbidity and Mortality Weekly Report (MMWR). Malaria deaths following inappropriate malaria chemoprophylaxis - United States. MMWR 2001; 50: 597599.
  • 2
    Williams HA, Roberts J, Kachur SP et al. Malaria surveillance-United States, 1995. CDC Surveillance Summaries. MMWR 1999; 48 (01): 121. AMBIGUOUS (21 citations)
  • 3
    Newman RD, Barber AM, Roberts J et al. Malaria surveillance-United States, 1999. CDC Surveillance Summaries. MMWR 2002; 5 (01): 1528.
  • 4
    Kain KC, Macpherson DW, Kelton T et al. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. Can Med Assoc J 2001; 164: 654659.
  • 5
    Ryan ET, Wilson M, Kain KC. Illness after international travel. N Engl J Med 2002; 347: 505516. (PubMed) 12181406
  • 6
    Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance I. Currently recommended drug regimens. Clin Infect Dis 2001; 33: 226234. (PubMed) 11418883
  • 7
    Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance II. Drugs that may be available in the future. Clin Infect Dis 2001; 33: 381385. (PubMed) 11438908
  • 8
    Shanks GD, Gordon DM, Klotz FW et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27: 494499. 9770146
  • 9
    Lell B, Luckner D, Ndjave M et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351: 709713. (PubMed) 9504515
  • 10
    Sukwa TY, Mulenga M, Chisdaka N et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60: 521525. (PubMed) 10348223
  • 11
    Berman JD, Nielsen R, Chulay JD et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95: 429432. (PubMed) 11579890
  • 12
    Hogh B, Clarke P, Camus D et al. Atovaquone/proguanil versus chloroquine/proguanil for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Lancet 2000; 356: 18881894. (PubMed) 11130385
  • 13
    Overbosch D, Schilthuis HS, Bienzle U et al. Atovaquone/proguanil versus mefloquine for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Clin Infect Dis 2001; 33: 10151021. (PubMed) 11528574
  • 14
    Ling J, Baird JK, Fryauff DJ et al. Randomized, double-blind, placebo-controlled evaluation of Malarone for prophylaxis of P. vivax and P. falciparum malaria in non-immune transmigrants to Papua. Clin Infect Dis 2002; 35: 825833. 12228819
  • 15
    van der Berg JD, Duvenage CS, Roskell NS et al. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum in South Africa. Clin Ther 1999; 21: 741749. 10363739
  • 16
    Faucher JF, Binder R, Missinou MA et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 11471154. (PubMed) 12410473
  • 17
    Nasveld PE, Edstein MD, Kitchener SJ et al. Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Comparison of the effectiveness of atovaquone/proguanil combination and doxycycline in the chemoprophylaxis of malaria in Australian Defense Force personnel [abstract no. 16]. Am J Trop Med Hyg 2000; 62 (Suppl 3) 139.
  • 18
    Schlagenhauf P, Tschopp A, Johnson R et al. Program and Abstracts of the 51st Annual Meeting of the American Society of Tropical Meidicine. Randomised, double-blind, four-arm study of the adverse event profiles of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa. [abstract 568]. Am J Trop Med Hyg 2002; 67 (Suppl 2) 354355.
  • 19
    Camus D, Malvy D, Schilthuis H et al. Program and Abstracts of the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Malarone versus chloroquine/proguanil for malaria prophylaxis in paediatric travellers. [abstract no. 579]. Am Soc Trop Med Hyg 2001; 65 (Suppl 3) 344345.
  • 20
    Overbosch D, Camus D, Clarke P et al. Program and Abstracts of the 51st annual meeting of the American Society of Tropical Medicine and Hygiene. Atovaquone/proguanil: A summary of safety and efficacy in clinical trials of pediatric, non-geriatric adult and geriatric travelers. [abstract no. 264]. Am Soc Trop Med Hyg 2002; 67 (Suppl 2) 228229.
  • 21
    Beerahee M. Clinical pharmacology of atovaquone and proguanil hydrochloride. J Travel Med 1999; 6 (Suppl 1) 1317.
  • 22
    Product Information: Malarone brand of atovaquone and proguanil hydrochloride tablets. 2002 Research Triangle Park , NC GlaxoSmithKline. AMBIGUOUS (548864 citations)
  • 23
    Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43: 13341339. (PubMed) 10348748
  • 24
    van Vugt M, Leonardi E, Phaipun L et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002; 35: 14981504. (PubMed) 12471569
  • 25
    Looareesuwan S, Viravan C, Webster HK et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 6266. (PubMed) 8651372
  • 26
    Korsinczky M, Kotecka B, Saul A et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44: 21002108. 10898682
  • 27
    Fivelman QL, Butcher GA, Adagu IS et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malaria Journal 2002; 1: 17. 12057021
  • 28
    Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil (Malarone) resistant Plasmodium falciparum malaria acquired by a non-immune traveler to East Africa. Clin Infect Dis 2003 [in press]. AMBIGUOUS (802 citations)